Belite Bio, Inc. · NASDAQ:BLTE
Belite Bio — Q1 2026 Earnings Presentation
7 slides from Belite Bio's earnings presentation, May 20, 2026
Slide 1: Q1 2026 Financial Results Conference Call
Q1 2026 Financial Results Conference Call May 20, 2026, 4:30 p.m. ET Nasdaq: BLTE BELITE BIO / 1
Slide 2: Belite Bio Executive Team
Belite Bio Executive Team Belite Management Team Tom Lin, MMED, PhD, MBA Hendrik Scholl, MD, MA Nathan Mata, PhD Hao-Yuan Chuang, CFA, MBA, FRM (Chairman, CEO) (CMO) (CSO) (CFO) • 16+ years of executive management • 25+ years of expertise in treating retinal • 15+ years of ophthalmic drug • 16+ year
Slide 3: Forward-Looking Statements and Legal Disclaimer
Forward-Looking Statements and Legal Disclaimer This presentation (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire,
Slide 4: Belite Bio Pipeline Overview & Updates
Belite Bio Pipeline Overview & Updates PRECLINICAL PHASE 1 PHASE 2 PHASE 3 NDA Stargardt Disease (STGD1) • Ph2, 2-year treatment, completed (13 subjects) • Ph3, 2-year treatment, global trial (“DRAGON” Study) completed (104 subjects) Tinlarebant • Ph2/3, 2-year treatment, global trial (“DRAGON II” S
Slide 5: Q1 2026 Financial Results
Q1 2026 Financial Results For more info please visit: www.belitebio.com
Slide 6: 2026 First Quarter Financial Results
2026 First Quarter Financial Results For the Three Months Ended March 31 For the Three Months Ended March 31 (In thousand USD) (GAAP)* (Non-GAAP)* 2025 2026 2025 2026 Total operating expenses 15,517 32,684 8,847 19,488 - R&D 9,396 15,661 7,389 13,806 - SG&A 6,121 17,023 1,458 5,682 Net loss (14,277)
Slide 7: Q&A
Q&A For more info please visit: www.belitebio.com